Payments from drug companies to physicians are associated with higher volume and more expensive opioid analgesic prescribing.

Our findings add to the growing public policy concern that payments from opioid drug manufacturers can influence physician prescribing. Interventions are needed to reduce such promotional activities or to mitigate their influence.